FDA Pulmonary-Allergy Advisory Cmte
Executive Summary
Session, scheduled for Sept. 4-5, wili be an update on theophylline. Topics to be covered include bioavailability, pharmacodynamics, extrapulmonary effects, and methylxanthine toxicity. Meeting will be jointly sponsored with American Academy of Allergy and Immunology